{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:18Z","timestamp":1793747058331,"version":"4.6.1"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.intimp.2026.117042","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:55:47Z","timestamp":1781913347000},"page":"117042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Folate receptor-\u03b1 targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies"],"prefix":"10.1016","volume":"185","author":[{"given":"Bishal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhisekh","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallvi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117042_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers17020217","article-title":"The role of cytoreductive surgery in platinum-resistant ovarian cancer (PROC): a systematic review","volume":"17","author":"Sideris","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117042_bb0010","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.117042_bb0015","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2026.117042_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108058","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer","volume":"222","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0025","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0035","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0045","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2023.3","article-title":"Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer","volume":"25","author":"Muaibati","year":"2023","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0050","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0055","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117042_bb0060","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2026.117042_bb0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10565-025-10027-5","article-title":"Advancing oral cancer care: nanomaterial-driven diagnostic and therapeutic innovations","volume":"41","author":"Chen","year":"2025","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.intimp.2026.117042_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-nutr-072610-145133","article-title":"Mechanisms of membrane transport of folates into cells and across epithelia","volume":"31","author":"Zhao","year":"2011","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.intimp.2026.117042_bb0075","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/jps.20457","article-title":"Folate receptor-mediated drug targeting: from therapeutics to diagnostics","volume":"94","author":"Hilgenbrink","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2026.117042_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/ar7000815","article-title":"Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases","volume":"41","author":"Low","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0085","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.intimp.2026.117042_bb0090","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.106.117648","article-title":"Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates","volume":"321","author":"Yang","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2026.117042_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117042_bb0100","doi-asserted-by":"crossref","first-page":"1138690","DOI":"10.3389\/fmed.2023.1138690","article-title":"Fallopian tubal histogenesis of ovarian endometriosis\u2014a study of folate receptor-alpha expression","volume":"10","author":"Wang","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0105","doi-asserted-by":"crossref","first-page":"L1335","DOI":"10.1152\/ajplung.2001.280.6.L1335","article-title":"Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting","volume":"280","author":"Danilov","year":"2001","journal-title":"Am J Physiol Cell Mol Physiol."},{"key":"10.1016\/j.intimp.2026.117042_bb0110","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","article-title":"Designing antibodies as therapeutics","volume":"185","author":"Carter","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117042_bb0115","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrm2523","article-title":"From cells to organs: building polarized tissue","volume":"9","author":"Bryant","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2026.117042_bb0120","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117042_bb0125","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-\u03b1 targeting: first in-human results","volume":"17","author":"van Dam","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0130","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13029","article-title":"Cellular models of development of ovarian high-grade serous carcinoma: a review of cell of origin and mechanisms of carcinogenesis","volume":"54","author":"Mei","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.intimp.2026.117042_bb0140","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117042_bb0145","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","article-title":"Expression of folate receptor-\u03b1 (FRA) in gynecologic malignancies and its relationship to the tumor type","volume":"32","author":"O\u2019Shannessy","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.intimp.2026.117042_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling and cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2026.117042_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254532","article-title":"Therapeutic strategies targeting folate receptor \u03b1 for ovarian cancer","volume":"14","author":"Mai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117042_bb0165","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age","volume":"17","author":"Liu","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.117042_bb0170","first-page":"275","article-title":"Breast cancer progression and its theranostic management via folate-directed targeting of glycoprotein receptor","volume":"13","author":"Girigoswami","year":"2025","journal-title":"Med. Sci."},{"key":"10.1016\/j.intimp.2026.117042_bb0175","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.3390\/ijms26167687","article-title":"Interobserver agreement in immunohistochemical evaluation of folate receptor alpha (FR\u03b1) in ovarian cancer: a multicentre study","volume":"26","author":"Zannoni","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117042_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0185","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.5858\/arpa.2023-0149-OA","article-title":"Development of an FR\u03b1 companion diagnostic immunohistochemical assay for mirvetuximab soravtansine","volume":"148","author":"James","year":"2024","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0190","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117042_bb0195","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s12094-025-04179-3","article-title":"Folate receptor alpha in platinum-resistant ovarian cancer: prevalence in a multicenter polish cohort and review of the evidence","volume":"28","author":"Borowczak","year":"2026","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0200","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.intimp.2026.117042_bb0205","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0210","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0215","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0220","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3389\/fonc.2019.01537","article-title":"Ovarian cancer targeted theranostics","volume":"9","author":"Nimmagadda","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0225","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2013.03.002","article-title":"Farletuzumab, a monoclonal antibody against folate receptor alpha, in relapsed platinum-sensitive ovarian cancer","volume":"129","author":"Armstrong","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0230","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.2015.63.2596","article-title":"A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse","volume":"34","author":"Vergote","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0235","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cei\/uxab020","article-title":"Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies","volume":"209","author":"Osborn","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2026.117042_bb0240","doi-asserted-by":"crossref","first-page":"52045","DOI":"10.18632\/oncotarget.19090","article-title":"Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity of farletuzumab","volume":"8","author":"Kline","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2026.117042_bb0245","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/cea.12178","article-title":"Epidemiological associations of allergy, IgE and cancer","volume":"43","author":"Josephs","year":"2013","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.intimp.2026.117042_bb0250","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1038\/s41467-023-39679-9","article-title":"Safety and anti-tumour activity of the IgE antibody MOv18 in patients with cancer: a phase 1, first-in-human, dose-escalation trial","volume":"14","author":"Spicer","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117042_bb0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2026.117042_bb0260","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0265","first-page":"851","article-title":"Patient-reported outcomes from the MIRASOL trial of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"9","author":"Konner","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0270","first-page":"1399","article-title":"Mirvetuximab soravtansine-gynx: first approval in folate receptor alpha-positive platinum-resistant ovarian cancer","volume":"83","author":"Richardson","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.117042_bb0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor alpha in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0280","article-title":"Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology","volume":"46","author":"Richardson","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.intimp.2026.117042_bb0285","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/ICO.0000000000001805","article-title":"Ocular toxicity of mirvetuximab","volume":"38","author":"Corbelli","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.intimp.2026.117042_bb0290","article-title":"Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine","volume":"47","author":"Hendershot","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.intimp.2026.117042_bb0295","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1111\/cas.14898","article-title":"Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in preclinical models of folate receptor alpha-positive cancer","volume":"112","author":"Furuuchi","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.intimp.2026.117042_bb0300","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21873\/anticanres.17391","article-title":"Eribulin induction of immunogenic cell death","volume":"45","author":"Zang","year":"2025","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0305","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.117042_bb0310","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-\u03b1-positive solid tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0315","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/diagnostics14080819","article-title":"CAR-T cell therapy in ovarian cancer: where are we now?","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.intimp.2026.117042_bb0320","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0325","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","article-title":"Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment","volume":"5","author":"Scarf\u00f2","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117042_bb0330","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cancers10080242","article-title":"The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy","volume":"10","author":"Rodriguez","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117042_bb0335","doi-asserted-by":"crossref","first-page":"1104547","DOI":"10.3389\/fonc.2023.1104547","article-title":"Understanding CAR T cell therapy and its role in ovarian cancer and peritoneal carcinomatosis","volume":"13","author":"Dom\u00ednguez-Prieto","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0340","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1479-5876-10-157","article-title":"A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer","volume":"10","author":"Kandalaft","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0345","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1002\/cam4.2378","article-title":"Final analysis of a phase I\/IIa trial of the folate-binding protein vaccine E39 + GM-CSF to prevent recurrence in ovarian and endometrial cancer patients","volume":"8","author":"Brown","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0350","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/1078-0432.CCR-17-2499","article-title":"Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients","volume":"24","author":"Kalli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2024.07.675","article-title":"Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: a randomized, multicenter clinical trial","volume":"189","author":"Gupta","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0360","first-page":"1073","article-title":"Immunotherapy in ovarian cancer","volume":"32","author":"Zsiros","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.intimp.2026.117042_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000829","article-title":"Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial","volume":"8","author":"Zamarin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.117042_bb0370","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin in combination versus pegylated liposomal doxorubicin alone in patients with platinum-resistant ovarian cancer","volume":"31","author":"Naumann","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0375","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.01.010","article-title":"A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin in combination versus pegylated liposomal doxorubicin in participants with platinum-resistant ovarian cancer: PROCEED","volume":"137","author":"Oza","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0380","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1158\/0008-5472.CAN-05-2034","article-title":"BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors","volume":"65","author":"Gibbs","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0385","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","article-title":"Folate-targeted therapeutic and imaging agents for cancer","volume":"13","author":"Low","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.intimp.2026.117042_bb0390","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/php.13173","article-title":"The course of immune stimulation by photodynamic therapy: bridging fundamentals of photochemically induced immunogenic cell death to the enrichment of T-cell repertoire","volume":"95","author":"Nath","year":"2019","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.intimp.2026.117042_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.686303","article-title":"Photodynamic therapy for the treatment and diagnosis of cancer: a review of the current clinical status","volume":"9","author":"Gunaydin","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.intimp.2026.117042_bb0400","first-page":"3554","article-title":"Folate receptor targeted photodynamic therapy: a novel way to stimulate anti-tumor immune response in intraperitoneal ovarian cancer","volume":"15","author":"Baydoun","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117042_bb0405","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/cancers12092491","article-title":"Photodynamic diagnosis and therapy for peritoneal carcinomatosis: emerging perspectives","volume":"12","author":"Kim","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.117042_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108952","article-title":"Preoperative [18F]fluoro-PEG-folate PET\/CT in advanced stage epithelial ovarian cancer: a safety and feasibility study","volume":"138-139","author":"Ciggaar","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.intimp.2026.117042_bb0415","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13550-020-00624-2","article-title":"Radiation dosimetry of ^18F-AzaFol: a first in-human use of a folate receptor PET tracer","volume":"10","author":"Gnesin","year":"2020","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0420","article-title":"Development and evaluation of a single domain antibody radioligand targeting folate receptor alpha with low kidney retention","volume":"14","author":"Dewulf","year":"2024","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.intimp.2026.117042_bb0425","first-page":"1422","article-title":"Folate receptor targeted nanoparticles containing niraparib and doxorubicin for the treatment of ovarian cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.117042_bb0430","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/acs.biomac.5b01189","article-title":"Folate receptor targeted delivery of siRNA and paclitaxel to ovarian cancer cells via folate-decorated triblock copolymer micelleplexes","volume":"17","author":"Jones","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.intimp.2026.117042_bb0435","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-alpha-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against folate receptor-alpha-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2026.117042_bb0440","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0445","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2026.117042_bb0450","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0455","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","article-title":"Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma","volume":"191","author":"Rushton","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0460","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","article-title":"Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes","volume":"128","author":"Bax","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.117042_bb0465","first-page":"961","article-title":"Liposome-folate conjugate targeted to folate receptors for systemic delivery and tumor localization of liposomal drugs in cancer","volume":"81","author":"Gabizon","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117042_bb0470","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0475","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0480","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1080\/14796694.2024.2372241","article-title":"Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FR\u03b1-high platinum-sensitive ovarian cancer","volume":"20","author":"O\u2019Malley","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0485","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","article-title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","volume":"185","author":"Richardson","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.117042_bb0490","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117042_bb0495","first-page":"311","article-title":"Nanoparticle-mediated photodynamic therapy for ovarian cancer: mechanisms, applications and future directions","volume":"22","author":"Bhatta","year":"2024","journal-title":"J. Nanobiotechnol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600888X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600888X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:33:13Z","timestamp":1784230393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600888X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":99,"alternative-id":["S156757692600888X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117042","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folate receptor-\u03b1 targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117042"}}